ArticleJournal of the Korean Society of Radiology2026
망막모세포종에 대한 일차 및 대안 경로를 통한 동맥 내 화학요법의 안구 보존 결과: 인도네시아 단일 기관 경험.
Article in Journal of the Korean Society of Radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy and safety of intra-arterial chemotherapy (IAC) delivered via the internal carotid artery (ICA) and external carotid artery (ECA) anastomoses at a single Indonesian center. Materials and Methods: A retrospective chart review was conducted of consecutive retinoblastoma cases treated with IAC between June 2022 and September 2025. Procedures were performed under general anesthesia via ultrasound-guided femoral arterial access. ICA catheterization using a diagnostic catheter was followed by ophthalmic artery (OA) cannulation with a microcatheter. Alternative access routes included the vertebrobasilar circulation and ECA branches (middle meningeal, internal maxillary, and zygomatico-orbital arteries). Melphalan (4-5 mg) was the primary agent for International Classification of Retinoblastoma Groups B-C, whereas topotecan and carboplatin were added for recurrent or advanced disease (Groups D-E). Recorded outcomes included the number of sessions, access route, procedure-related complications, globe salvage, and enucleation. Ocular survival was analyzed using Kaplan-Meier methods, and predictors of enucleation were assessed using multivariable Cox proportional hazards modeling. Results: Twenty-four eyes of 24 patients (median age, 13.7 months) underwent 65 IAC sessions (45 via ICA and 20 via ECA). Globe salvage was achieved in 19 of 24 eyes (79.2%) at 6 months, and 14 of 24 eyes (58.3%) remained enucleation-free at 39 months. Ocular survival was lower for ECA compared with ICA access ( Conclusion: In this cohort, IAC provided favorable globe salvage with an acceptable safety profile. However, ECA access was associated with an increased risk of enucleation; therefore, direct OA access via the ICA is preferable when feasible. Larger prospective studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.